<DOC>
	<DOCNO>NCT00685113</DOCNO>
	<brief_summary>This multicenter study evaluate efficacy safety 2 different dos DR-3001 . For eligible subject duration study approximately 20 week ; consist 4-week screening period , 12-week treatment period 4-week follow-up period . Subjects physical laboratory exam , include blood draw schedule visit . Subjects require insert vaginal ring ( replace every 4 week ) keep daily record toilet void ( include time , type volume ) 3 day several specified time point .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Efficacy Safety DR-3001 Women With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Women 18 year age old , ambulatory , history presentation consistent urge incontinence â‰¥ 6 month Able distinguish stress urge incontinence During Screening Period able demonstrate presence overactive bladder urge incontinence base diary entry Others dictate FDAapproved protocol Stress incontinence , continuous incontinence overflow urinary incontinence Chronic illness , neurological dysfunction injury could cause incontinence Pregnant , breastfeeding , give birth last 6 month Others dictate FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>